http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04244a8246306d5955e7519769cbfa85
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Andreeff Michael Andreeff |
| name | Michael Andreeff |
| given-name | Michael |
| organization-name | Department of Leukemia, The University of Texas at MD Anderson Cancer Center, Houston, TX, USA; 1Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy and Departments of; 3Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston;; Departments of Leukemia and Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas, Maryland Anderson Cancer Center , Houston, Texas , USA The University of Texas M. D. Anderson Cancer Center, Houston; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Discovery Oncology, Roche Research Center, Hoffmann-La Roche Inc, Nutley, NJ. U.T.M.D. Anderson Cancer Center, Department of Hematology, Box 24, I5I5 Holcombe Blvd., Houston, TX 77030 (713) 792-8750. Section of Molecular Hematology and Therapy Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA From The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Progenitor, Inc, Menlo Park, CA. From the Cytokine Research Laboratory, Department of Experimental Therapeutics, and the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston. From the Department of Blood and Marrow Transplantation, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and The Burnham Institute, La Jolla, CA. Authors' Affiliations: Departments of 1Leukemia, 2Molecular and Cellular Oncology, and 3Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 4Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, South Carolina; and 5Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Departments of 1Neurosurgery, 2Neuro-oncology, and 3Stem Cell Transplantation and 4Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and 5Division of Neurosurgery, Department of Surgery, The University of British Columbia, Vancouver, British Columbia, Canada Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX , USA From the Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN; and the Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, M. D. Anderson Cancer Center, Houston, TX. From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, and the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX. Section of Molecular Hematology and Therapy, Departments of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX;; Section of Molecular Hematology and Therapy, Departments of Leukemia and Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston, TX USA Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation and Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA 3Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; and Section of Molecular Hematology and Therapy, Departments of Stem Cell Transplantation and Cellular Therapy, The University of Texas-M.D. Anderson Cancer Center, Houston, Texas, USA From the Section of Molecular Hematology and Therapy, Department of Hematology, and Department of Clinical Investigations, The University of Texas M.D. Anderson Cancer Center, Houston; and the Institute of Hematology, University of Catania, Italy. Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Leukemia, Houston, Texas, USA Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA Department of Leukemia, Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, The University of Texas, Houston, Texas and 2Cancer Biology, Ortho Biotech Oncology Research and Development, Beerse, Belgium Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation, and Institute of Nuclear Medicine, University Hospital Dresden, Dresden, Germany. Department of Leukemia, MD Anderson Cancer Center, Texas State University, Houston, TX, USA Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas From the Departments of Leukemia, Hematopathology, Stem Cell Transplantation and Cellular Therapy, and Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX; and Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD. From the Departments of Leukemia, Bioimmunotherapy, and Blood and Marrow Transplant, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the National Cancer Institute, Bethesda, MD. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. From the Department of Leukemia, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX. From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada. 15M. D. Anderson Cancer Center, Houston, Texas; and Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Leukemia, 2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston; and 3AROG Pharmaceuticals LLC, Dallas, Texas; Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Leukemia, 2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston; and 3AROG Pharmaceuticals LLC, Dallas, Texas Section of Molecular Hematology and Therapy Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA 1Blood and Marrow Transplantation, Departments of; 3Leukemia, Section of Molecular Hematology and Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Stem Cell Transplantation and Cellular Therapy, and Section of Molecular Hematology and Therapy, Department of Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Leukemia The University of Texas—M.D. Anderson Cancer Center Houston Texas The University of Texas, MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and Section of Molecular Hematology and Therapy, Department of Leukemia; 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Departments of; 2Leukemia and 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Authors' Affiliations: 1Discovery Oncology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, New Jersey; 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 3Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey Medical School, Newark, New Jersey From the University of Texas M. D. Anderson Cancer Center, Houston, TX. University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA Authors' Affiliations: 1Department of Leukemia; 2Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas; 3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; 4Division of Hematology/Department of Medicine; 5Department of Epidemiology, University of Washington, Seattle, Washington; and 6National Cancer Institute, Rockville, Maryland From the Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, and Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Department of Biochemistry, University of Illinois at Urbana-Champaign, Champaign, IL. From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, and the Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston. 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy,; 2Leukemia, From the Departments of Bioimmunotherapy, Hematology, and Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Fred Hutchinson Cancer Research Center, Seattle, WA. Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Leukemia MD Anderson Cancer Center Houston, TX USA Institute of Nuclear Medicine, University Hospital Carl Gustav Carus, Dresden, Germany. Department of Leukemia,; Department of Stem Cell Transplantation, and 1The Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, and 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, and 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, 2Department of Leukemia, 3Department of Stem Cell Transplantation and Cellular Therapy, and 4Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas; 6Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida; 7Department of Biochemistry, University of Crete, School of Medicine, Heraklion, Greece; 8Reata Pharmaceuticals, Irving, Texas; and 9Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, 2Department of Leukemia, 3Department of Stem Cell Transplantation and Cellular Therapy, and 4Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas; 6Cancer Research Institute, M.D. Anderson Cancer Center Orlando, Orlando, Florida; 7Department of Biochemistry, University of Crete, School of Medicine, Heraklion, Greece; 8Reata Pharmaceuticals, Irving, Texas; and 9Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada 1Leukemia and Departments of; 2Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Authors' Affiliations: Departments of 1Leukemia, 2Pediatrics, and 3Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 4Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 6The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio; 7AbbVie Inc., North Chicago, Illinois; and 8Department of Laboratory Medicine, University of California San Francisco, San Francisco, California; 9Department of Internal Medicine III, University Hospital of Ulm, Ulm; 10MLL Munich Leukemia Laboratory, Munich, Germany Clinic and Policlinic for Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany. Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Molecular Hematology and Therapy, MD Anderson Cancer Center, Houston, TX; and University of Texas M. D. Anderson Cancer Center Houston Authors' Affiliations: 1Section of Molecular Hematology and Therapy; Departments of; 2Leukemia and 2Leukemia Department and; 3Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston Texas; From the Pulmonary Engineering Group, Department of Anesthesiology and Intensive Care Medicine, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany (A.G., A.B., N.C., A.B., S.Z., C.U., P.M.S., T.K., and M.G.d.A.); Department of Electric Engineering, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil (A.B.); Institute of Informatics and Biometry, Dre Departments of Stem Cell Transplantation & Cellular Therapy, Molecular Hematology & Therapy, and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center; From the Center for Cell and Gene Therapy, Baylor College of Medicine; and Molecular Hematology and Therapy, M. D. Anderson Cancer Center, Houston, TX. From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, the Department of Leukemia, and the Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX. 1The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Stem Cell Transplantation, and Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX From the Departments of Leukemia and Molecular Hematology, and Division of Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology, Singapore General Hospital, Singapore. Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA From the Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario; Maisonneuve-Rosemont Hospital; Aegera Therapeutics Inc, Montreal, Quebec, Canada; M. D. Anderson Cancer Center, Houston, TX; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; and Johns Hopkins University, Baltimore, MD. University of Texas MD Anderson Cancer Center, Houston, TX, USA 5Molecular Hematology and Therapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas 1Blood and Marrow Transplantation and Departments of Authors' Affiliations: Departments of 1Neurosurgery 2Neuro-Oncology, and 3Molecular Hematology and Therapy, 4The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Department of Neurosurgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan From the Departments of Blood and Marrow Transplantation and Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX. Department of Leukemia and Department of Leukemia MD Anderson Cancer Center The University of Texas Houston TX USA 2Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 1Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, Departments of 1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas 3Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas 3Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 2Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org. Section of Molecular Hematology & Therapy, Department of Leukemia, and; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. From the Departments of Cell Biology and Hematology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. From the Section of Molecular Hematology and Therapy, Departments of Blood and Marrow Transplantation, Biostatistics, and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Departments of Clinical Pathology and Biochemistry, Juntendo University of Medicine, Tokyo, Japan. Departments of Leukemia and; Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX;; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Blood and Marrow Transplantation, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030 Authors' Affiliations: 1Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas; Authors' Affiliations: 1Eutropics Pharmaceuticals, Cambridge, Massachusetts; 2Molecular Hematology and Therapy, Department of Stem Cell Transplantation; 3Division of Cancer Medicine, Department of Leukemia; and 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas From the Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, Department of Biostatistics, and Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Clinical Pathology, Juntendo University of Medicine, Tokyo, Japan. Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, 2Department of Leukemia, and 3Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center; 4The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas and 5Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung, Taiwan; Authors' Affiliations: 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, 2Department of Leukemia, and 3Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center; 4The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas and 5Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung, Taiwan Molecular Hematology and Therapy Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas Authors' Affiliations: 1Division of Hematology & Hemostaseology and 2Bone Marrow Transplantation Unit, Department of Internal Medicine I and 3Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria; 4Haematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom; 5Department of Leukemia and Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; 6Paul O'Gorman Leukaemia Research Centre, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; 7APHP Hôpital Saint Louis; 8Inserm U940; 9Université Paris Diderot, Paris, France; and 10Terry Fox Laboratory, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada Authors' Affiliations: Departments of1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Leukemia, Division of Cancer Medicine, and 3Hematopathology, and 4Molecular Hematology and Therapy Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; 5Reata Pharmaceuticals, Inc., Irving, Texas; 6Massachusetts General Hospital; 7Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School; 8Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute; 9Dana-Farber Cancer Institute; 10Division of Hematology/Oncology, Massachusetts General Hospital; 11Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and 12Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas; Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas 3Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas From The University of Texas M. D. Anderson Cancer Center, Houston, TX. From the Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, and the Departments of Bioimmunotherapy and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; The University of Florida, Gainesville; Department of Medicine, Dartmouth College, Department of Chemistry and Dartmouth Medical School, Department of Pharmacology, Hanover, NH. From the Department of Blood and Bone Marrow Transplantation and Biomathematics, University of Texas MD Anderson Cancer Center, Houston, TX. Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston; Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Departments of Molecular Hematology & Therapy and Stem Cell Transplantation & Cellular Therapy and; Leukemia, University of Texas M. D. Anderson Cancer Center, Houston 1Section of Molecular Hematology and Therapy, Departments of Blood and Marrow Transplantation, From the Departments of Bioimmunotherapy, Hematology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Department of Leukemia, Section of Molecular Hematology and Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Leukemia, Section of Molecular Hematology and Therapy, MD Anderson Cancer Center, Houston, TX USA Authors' Affiliations: Departments of 1Molecular and Cellular Oncology and 2Breast Medical Oncology, and 3Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center; and 4Graduate School of Biomedical Sciences, The University of Texas, Houston, Texas; 5Department of Medicine, Harvard Medical School, Boston, Massachusetts; and 6Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical, University and Hospital, Taichung, Taiwan Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston;; Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston 1Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston Texas.; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston Texas. Authors' Affiliations: Departments of 1Radiation Oncology, 2Leukemia, 3Gynecologic Oncology, and 4Pathology, The University of Texas MD Anderson Cancer Center; and 5The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas From the Departments of Cell Biology and Hematology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX. Department of Leukemia,; Section of Molecular Hematology and Therapy, and From the Departments of Leukemia, Hematopathology, Experimental Therapeutics, Blood and Marrow Transplantation, and the Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Dresden, Germany 1Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation and Departments of; 2Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA From the University of Texas MD Anderson Cancer Center, Houston, TX; the Ontario Cancer Institute, the Princess Margaret Hospital, the University Health Network, and the McLaughlin Center for Molecular Medicine, Toronto, Ontario, Canada; the Burnham Institute, and the Torrey Pines Institute for Molecular Studies, La Jolla, CA. Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, USA From the Departments of LeukemiaBiomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children’s Memorial Hospital of Chicago, Chicago, IL. Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Leukemia,; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 9Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. From the University of Texas M. D. Anderson Cancer Center, Houston, TX; the Division of Medical Oncology I, Regina Elena Cancer Institute, Rome, Italy; and Yale University School of Medicine, New Haven, CT. Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2Blood and Marrow Transplantation, Section of Molecular Hematology; and Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD... From the Burnham Institute, Program on Apoptosis and Cell Death Research, La Jolla, CA, and the M. D. Anderson Cancer Center, Section of Molecular Hematology and Therapy, Houston, TX. 1Section of Molecular Hematology and Therapy and the Departments of Blood and Marrow Transplantation,; 4Leukemia at The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Section of Molecular Hematology and Therapy, University of Texas M. D. Anderson Cancer Center, Houston; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 2Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, and; 2Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston; and From The Burnham Institute and University of California–San Diego, La Jolla, CA; Tissue Proteomics Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD; The University of Texas MD Anderson Cancer Center, Houston; ISIS Pharmaceuticals, Carlsbad, CA; and Dartmouth Medical School, Hanover, NH. Department of Molecular Hematology and Therapy, M.D. Anderson Cancer Center, Houston, TX 77030 From the Department of Hematology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd Houston, TX 77030, USA *Hematology and From the Departments of Leukemia, Biostatistics, Bone Marrow Transplantation, and Bioimmunotherapy, M.D. Anderson Cancer Center, Houston, TX. From the Departments of Internal Medicine I and Nuclear Medicine and the Ludwig Boltzmann Institut for Experimental Endocrinology, University of Vienna, Austria; and the M.D. Anderson Cancer Center, University of Texas, Houston. Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, M. D. Anderson Cancer Center, The University of Texas, Houston, Texas Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, University of Texas, Houston From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston. 1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
Incoming Links
Total number of triples: 695.